Ultragenyx Pharmaceutical Inc. 10-Q

Item 5. Other Information None. 67 I tem 6. Exhibits Incorporated by Reference Exhibit Number Exhibit Description Form Date Number Furnished or Filed Herewith 3.1 Amended and Restated Certificate of Incorporation 8-K 2/5/2014 3.1 3.2 Amended and Restated Bylaws 8-K 2/5/2014 3.2 10.1 Offer Letter between Mardi C. Dier and Ultragenyx Pharmaceutical Inc. dated August 28, 2020. 8-K 9/2/2020 10.1 10.2 Amendment dated October 9, 2020 to the Offer Letter between Mardi C. Dier and Ultragenyx Pharmaceutical Inc. dated August 28, 2020 8-K 10/13/2020 10.1 10.3 Amendment, dated as of August 28, 2020, to Transition Letter Agreement between Shalini Sharp and Ultragenyx Pharmaceutical Inc. dated March 5, 2020. 8-K 9/2/2020 10.2 10.4 Amendment No. 2 dated October 8, 2020 to the Transition Letter Agreement between Shalini Sharp and Ultragenyx Pharmaceutical Inc. dated as of March 5, 2020, as amended on August 28, 2020 8-K 10/13/2020 10.2 10.5 Fourth Amended and Restated Amendment to Lease Agreement between Ultragenyx Pharmaceutical Inc. and ARE-MA Region No. 20, LLC X 31.1 Certification of Principal Executive Officer Required Under Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act X 31.2 Certification of Principal Financial Officer Required Under Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act X 32.1* Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and 18 U.S.C. 1350 X 101.INS XBRL Instance Document, formatted in Inline XBRL X 101.SCH Inline XBRL Taxonomy Extension Schema Document X 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document X 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document X 101.LAB Inline XBRL Taxonomy Extension Labels Linkbase Document X 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document X 104 Cover Page Interactive Data File, formatted in Inline XBRL (included in Exhibit 101). * The certification attached as Exhibit 32.1 that accompanies this Quarterly Report is furnished to, and not deemed filed with, the SEC and is not to be incorporated by reference into any filing of the Registrant under the Securities Act or the Exchange Act, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing. 68 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ULTRAGENYX PHARMACEUTICAL I NC . Date: October 27, 2020 By: /s/ Emil D. Kakkis Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer (Duly Authorized Officer) Date: October 27, 2020 By: /s/ Theodore A. Huizenga Theodore A. Huizenga Senior Vice President and Corporate Controller (Principal Accounting Officer) 69